Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events
To investigate immune checkpoint inhibitors (ICIs) induced pancreatic injury (ICIPI), the prognostic effect of COVID-19 vaccine on cancer patients, and whether COVID-19 vaccine increases the incidence of ICIPI. We conducted a retrospective study of 256 stage IV cancer patients treated with ICIs at T...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2358575 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850124083957596160 |
|---|---|
| author | Min Li Lingling Liao Wei Huang Hui Feng Wanqing Wang Nana Huang Zhiyan Zhao Yu Shi Jinglu Ye Kangsheng Gu |
| author_facet | Min Li Lingling Liao Wei Huang Hui Feng Wanqing Wang Nana Huang Zhiyan Zhao Yu Shi Jinglu Ye Kangsheng Gu |
| author_sort | Min Li |
| collection | DOAJ |
| description | To investigate immune checkpoint inhibitors (ICIs) induced pancreatic injury (ICIPI), the prognostic effect of COVID-19 vaccine on cancer patients, and whether COVID-19 vaccine increases the incidence of ICIPI. We conducted a retrospective study of 256 stage IV cancer patients treated with ICIs at The First Affiliated Hospital of Anhui Medical University from January 2020 to November 2022. Data collected included pancreatic enzyme levels, treatment outcomes, and vaccination status. Statistical significance was determined using the χ2 test and Kaplan-Meier method (p < .05). Compared to the control group, the vaccinated group (p < .0001) and the group with elevated pancreatic enzyme levels (p = .044) demonstrated higher disease control rates, indicating a direct benefit of vaccination and enzyme monitoring on treatment outcomes. Additionally, vaccinated patients demonstrated longer overall survival versus unvaccinated patients (23.9 months [95% CI, 22.3–25.5] vs 23.6 months [95% CI, 21.1–26.2], HR = 0.45 [95% CI, 0.24–0.86], p = .015) and progression-free survival (17.2 months [95% CI, 14.3–20.1] vs 13.7 months [95% CI, 11.3–16.1], HR = 0.54 [95% CI, 0.36–0.82], p = .004). Importantly, the analysis revealed no significant association between vaccination and pancreatic injury (p = .46). Monitoring pancreatic enzymes can effectively evaluate the therapeutic impact in patients using ICIs. Patients vaccinated against COVID-19 experience better immunotherapy outcomes without an increased risk of ICIPI. |
| format | Article |
| id | doaj-art-f636f6a042a14e9baf122765f32688bc |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-f636f6a042a14e9baf122765f32688bc2025-08-20T02:34:25ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2358575Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse eventsMin Li0Lingling Liao1Wei Huang2Hui Feng3Wanqing Wang4Nana Huang5Zhiyan Zhao6Yu Shi7Jinglu Ye8Kangsheng Gu9Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Medical Imaging, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaTo investigate immune checkpoint inhibitors (ICIs) induced pancreatic injury (ICIPI), the prognostic effect of COVID-19 vaccine on cancer patients, and whether COVID-19 vaccine increases the incidence of ICIPI. We conducted a retrospective study of 256 stage IV cancer patients treated with ICIs at The First Affiliated Hospital of Anhui Medical University from January 2020 to November 2022. Data collected included pancreatic enzyme levels, treatment outcomes, and vaccination status. Statistical significance was determined using the χ2 test and Kaplan-Meier method (p < .05). Compared to the control group, the vaccinated group (p < .0001) and the group with elevated pancreatic enzyme levels (p = .044) demonstrated higher disease control rates, indicating a direct benefit of vaccination and enzyme monitoring on treatment outcomes. Additionally, vaccinated patients demonstrated longer overall survival versus unvaccinated patients (23.9 months [95% CI, 22.3–25.5] vs 23.6 months [95% CI, 21.1–26.2], HR = 0.45 [95% CI, 0.24–0.86], p = .015) and progression-free survival (17.2 months [95% CI, 14.3–20.1] vs 13.7 months [95% CI, 11.3–16.1], HR = 0.54 [95% CI, 0.36–0.82], p = .004). Importantly, the analysis revealed no significant association between vaccination and pancreatic injury (p = .46). Monitoring pancreatic enzymes can effectively evaluate the therapeutic impact in patients using ICIs. Patients vaccinated against COVID-19 experience better immunotherapy outcomes without an increased risk of ICIPI.https://www.tandfonline.com/doi/10.1080/21645515.2024.2358575Immune checkpoint inhibitors (ICIs)immune-related pancreatic toxicitypancreatic enzymes; COVID-19 vaccine |
| spellingShingle | Min Li Lingling Liao Wei Huang Hui Feng Wanqing Wang Nana Huang Zhiyan Zhao Yu Shi Jinglu Ye Kangsheng Gu Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events Human Vaccines & Immunotherapeutics Immune checkpoint inhibitors (ICIs) immune-related pancreatic toxicity pancreatic enzymes; COVID-19 vaccine |
| title | Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events |
| title_full | Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events |
| title_fullStr | Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events |
| title_full_unstemmed | Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events |
| title_short | Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events |
| title_sort | patients with advanced cancer were treated with immune checkpoint inhibitors and injected with covid 19 vaccine to improve their prognosis without increasing pancreatic related adverse events |
| topic | Immune checkpoint inhibitors (ICIs) immune-related pancreatic toxicity pancreatic enzymes; COVID-19 vaccine |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2358575 |
| work_keys_str_mv | AT minli patientswithadvancedcancerweretreatedwithimmunecheckpointinhibitorsandinjectedwithcovid19vaccinetoimprovetheirprognosiswithoutincreasingpancreaticrelatedadverseevents AT linglingliao patientswithadvancedcancerweretreatedwithimmunecheckpointinhibitorsandinjectedwithcovid19vaccinetoimprovetheirprognosiswithoutincreasingpancreaticrelatedadverseevents AT weihuang patientswithadvancedcancerweretreatedwithimmunecheckpointinhibitorsandinjectedwithcovid19vaccinetoimprovetheirprognosiswithoutincreasingpancreaticrelatedadverseevents AT huifeng patientswithadvancedcancerweretreatedwithimmunecheckpointinhibitorsandinjectedwithcovid19vaccinetoimprovetheirprognosiswithoutincreasingpancreaticrelatedadverseevents AT wanqingwang patientswithadvancedcancerweretreatedwithimmunecheckpointinhibitorsandinjectedwithcovid19vaccinetoimprovetheirprognosiswithoutincreasingpancreaticrelatedadverseevents AT nanahuang patientswithadvancedcancerweretreatedwithimmunecheckpointinhibitorsandinjectedwithcovid19vaccinetoimprovetheirprognosiswithoutincreasingpancreaticrelatedadverseevents AT zhiyanzhao patientswithadvancedcancerweretreatedwithimmunecheckpointinhibitorsandinjectedwithcovid19vaccinetoimprovetheirprognosiswithoutincreasingpancreaticrelatedadverseevents AT yushi patientswithadvancedcancerweretreatedwithimmunecheckpointinhibitorsandinjectedwithcovid19vaccinetoimprovetheirprognosiswithoutincreasingpancreaticrelatedadverseevents AT jingluye patientswithadvancedcancerweretreatedwithimmunecheckpointinhibitorsandinjectedwithcovid19vaccinetoimprovetheirprognosiswithoutincreasingpancreaticrelatedadverseevents AT kangshenggu patientswithadvancedcancerweretreatedwithimmunecheckpointinhibitorsandinjectedwithcovid19vaccinetoimprovetheirprognosiswithoutincreasingpancreaticrelatedadverseevents |